Recombinant antibody production has emerged as a potent and ground-breaking technology in biomedical research. It has completely transformed the way scientists and researchers study illnesses, create ...

Antibodies are the number one immune cells that fight against infection and diseases. However, beyond their natural usage, biochemistry has devised several ways in which these antibodies can be ...

The history of antibody engineering and production in drug discovery can be traced back to the 1970s and 1980s [1] when scientists first began to explore the potential of using antibodies as ...

The development of early monoclonal antibody (mAb) therapies centered around the hybridoma platform requires the production of target antigen or immunogen and animal immunizations. This means there ...

Focusing on the establishment of Sino Biological‘s Center for Bioprocessing (C4B) in Houston, it highlights how the ...

Thank you to everyone who attended our webinar ‘Antibodies to watch in 2026‘ in association with the journal, mAbs. Below are ...

The antibody therapeutics industry is growing at an incredible pace. From early monoclonal therapeutic antibodies to modern bispecific and multispecific antibodies, single domain antibodies (VHHs), ...

The hybridoma methodology for developing monoclonal antibodies has been a lab staple for more than 30 years, and it still works great for immunohistochemistry and various cell biology techniques.

ROSEMONT, Ill.--(BUSINESS WIRE)--Proteintech, a global leader in antibodies, immunoassay kits, and recombinant proteins, today announced the launch of Multi-rAb Recombinant Secondary Antibodies, the ...

Despite the hundreds of millions of vials of blood drawn every year for medical testing, scientists have only scratched the surface of its diagnostic potential. The blood proteome — which includes all ...

Anglo-American life science firm AMSBIO announces a new range of recombinant antigens and antibodies for Zika virus, which are suited for the development of rapid assays and to overcome the problem of ...

Human respiratory syncytial virus (RSV) remains a significant public health concern, particularly for vulnerable populations such as infants, young children, and immunocompromised individuals. In this ...